|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||N/A|
Wall Street analysts expect AstraZeneca's top line to fall ~9.5% to $5.1 billion in 2Q17, compared to $5.6 billion in 2Q16. Its earnings per share are expected to be $0.42 in 2Q17.
For 2Q17, analysts estimate that GSK's revenues will rise ~11.4% to ~7.3 billion pounds, as compared to ~6.5 billion pounds for 2Q16.
In its earnings release on July 8, 2017, Novartis (NVS) reported flat revenues at constant currencies for 2Q17.